Stock Report

Sun Pharma introduces a novel class of drug, Fexuclue® in India for treatment of Erosive Esophagitis

Posted On : 2025-04-07 11:38:41( TIMEZONE : IST )

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and includes its subsidiaries and/or associate companies) today announced that it has launched Fexuprazan tablets 40 mg in India under the brand name "FEXUCLUE®". FEXUCLUE®, a novel potassiumcompetitive acid blocker (PCAB), is approved as a new treatment for adults with Erosive Esophagitis of all grades.

Sun Pharma has obtained rights from Daewoong Pharmaceutical Co Ltd, Korea, a biopharmaceutical company, to manufacture and commercialise FEXUCLUE®(Fexuprazan) in India. As per agreement terms, Daewoong will be entitled to upfront and milestone payments, including royalties.

Kirti Ganorkar, CEO - India Business, Sun Pharma, said, "Erosive Esophagitis is a serious condition that greatly affects patients' quality of life. Despite available treatments, there remains a significant unmet need in its management. FEXUCLUE® is a best-in-class treatment option with the potential to bridge this gap. At Sun Pharma, we are committed to introducing innovative medicines that enhance patients' quality of life."

Fexuprazan was evaluated in a double-blind, double-dummy, comparative Phase 3 study in adult Indian population. The primary efficacy measure was healing of Erosive Esophagitis which was confirmed endoscopically. The study met its primary endpoint. Over 95% of the patients achieved Erosive Esophagitis healing by 8 weeks. Fexuprazan was found to be well tolerated in Indian patients.

Shares of Sun Pharmaceutical Industries Limited was last trading in BSE at Rs. 1709.40 as compared to the previous close of Rs. 1770.10. The total number of shares traded during the day was 145024 in over 9400 trades.

The stock hit an intraday high of Rs. 1781.70 and intraday low of 1658.00. The net turnover during the day was Rs. 247704677.00.